
Your Feed
Building a Myeloma-Specific Score to Predict CAR-T Therapy Toxicities | Utkarsh Goel MD | #ASH24
Building a Myeloma-Specific Score to Predict CAR-T Therapy Toxicities | Utkarsh Goel MD | #ASH24
Golcadomide ± Rituximab in Relapsed/Refractory Large B-cell Lymphoma | Julio Chavez, MD, MS | #ASH24
Minority Access & Outcomes with Anti-BCMA CAR T Therapy in Myeloma | Luca Paruzzo, MD | #ASH24
Minority Access & Outcomes with Anti-BCMA CAR T Therapy in Myeloma | Luca Paruzzo, MD | #ASH24
Golcadomide ± Rituximab in Relapsed/Refractory Large B-cell Lymphoma | Julio Chavez, MD, MS | #ASH24
Mosunetuzumab + Polatuzumab Shows Promising Outcomes in LBCL | Julio Chavez, MD, MS | #ASH24
Mosunetuzumab + Polatuzumab Shows Promising Outcomes in LBCL | Julio Chavez, MD, MS | #ASH24
Mosunetuzumab + Polatuzumab Shows Promising Outcomes in LBCL
Myeloma 11 Trial: Carfilzomib Quadruplet Enhances Overall Survival | Charlotte Pawlyn, MD | #ASH24


